I am thrilled to introduce our new company to you: Konplik Health, dedicated to developing Artificial Intelligence solutions for the health, pharmaceutical, and life sciences industries.
Konplik Health’s Artificial Intelligence (AI) business builds on 22 years of experience of MeaningCloud (the Text Analytics company), packaged in this new, independent company. The spin-off will allow both product and management teams to drive increased responsiveness to their customers’ particular needs and achieve faster growth through focused and fit-for-purpose operating models.
Konplik Health will begin operations immediately with the health-related assets from MeaningCloud, including its leading natural language processing, deep semantic analysis, AI platform, and adaptations specific to the life sciences. This, along with relevant clients such as Pfizer, who first trusted us with critical strategic projects, creates a strong operating entity.
We offer long-lasting and comprehensive experience in the field, with dozens of projects delivered worldwide to the most prominent companies in the sector, and we are here to stay.
We benefit significantly from the technology developed at MeaningCloud for Text Analytics and work done in the healthcare and pharmaceutical space, inheriting exclusive rights to evolve this technology independently.
In addition to the benefits of MeaningCloud’s technology, we also inherit integration capabilities and experience from MeaningCloud, including partnering with some of the most prominent players in the RPA market (Automation Anywhere) and the Data Science market (Dataiku, RapidMiner).
Innovation is in our DNA. Since we started doing business in 1998 as a spin-off from an AI lab at the Technical University of Madrid, we have always tried to stay ahead of technological advances. However, do not think of us just as a partner for innovation, but as a business partner that will permeate innovation in your company without any hassle.
The launch of Konplik Health is a natural progression that builds on ten years of effort with health-specific applications and five years since establishing ourselves in the United States under the MeaningCloud name. Standing on its own, Konplik Health gives identity and more visibility to our work in healthcare and pharmaceuticals, which has been growing significantly.
What do we do?
At present, we can divide our AI services into five categories.
- Search and evaluation for Drug Discovery
- Real-World Evidence
- Market Intelligence
- Predictive Analytics
- Robotic Process Automation
Accelerating Search and Evaluation for Drug discovery
The most commonly cited estimate suggests that it costs $800 million in R&D expenditure to launch a single new drug, most of which is sunk into failures. As the amount of potentially relevant external data sources expands, teams are tasked to provide even more analytics support for its Search & Evaluation (S&E) function. With limited human capital to take on these big data tasks, research companies need to:
- Automate their unstructured data collection efforts
- Provide easy access to both basic and predictive analytics
Our solutions amplify the ability to collect, organize, and analyze the vast amounts of external data culled from an ever-expanding number of sources in the following areas:
- Patent analysis
- Scientific literature analysis
- Gap analysis
- Multilingual coding (ICD, SNOMED, ATC, RxNorm)
Real-World Evidence is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from the analysis of data related to patient health status or the delivery of health care. Health providers and practitioners, and pharmaceutical companies are increasingly interested in discovering how a product is dosed and applied in clinical practice and in compliance and adherence to therapy. For this purpose, we analyze:
- Electronic Health Records (EHR)
- Patient-reported outcomes (Voice of the Patient)
- Claims and billing activities
- Product and disease registries
- Scientific literature
- Health data gathered from other sources (e.g., mobile devices)
A specific area related to Real World Evidence is the detection of adverse effects (ADR, Adverse Drug reactions). This activity is the primary focus in the field of Pharmacovigilance.
To succeed in the pharmaceutical marketplace, it is vital to stay up to date with developments and opportunities that can affect business. Market intelligence can provide all the information needed in one place:
- New areas of investment
- M&A and partnering opportunities
- Tendering intelligence
- Shortages intelligence
We leverage both structured and unstructured data to improve business through predictive analytics and process optimization:
- Customer Analytics
- Demand forecast
- Revenue and margin forecast
- Price forecast
- Price elasticity of demand
- Shortages-driven strategy
- People analytics
Robotic Process Automation (RPA)
Software bots are typically used to execute routine tasks, suggest actions, or engage in dialog.
These tools orchestrate processes, gathering data from heterogeneous sources, performing advanced analysis on them, and generating integrated results, sometimes including tasks carried by specialists (human in the loop) or artificial intelligence agents. Chatbots represent a specific case, as they are used to conduct an online chat conversation via text or text-to-speech, instead of providing direct contact with a live human agent.
More than just another AI company in the healthcare space
Artificial Intelligence is competitive, particularly in areas related to health. The number of startups created each year in this sector continues to increase at a rapid rate. However, we firmly believe there is a place for Konplik Health to thrive.
Konplik Health is focused. Spanning business aspects (market intelligence, extraction of insights from large volumes of documentation, pricing, patient feedback analysis) as well as medical ones (Pharmacovigilance, analysis of health records), we are starting with our own solutions for extracting insights from textual sources; however, we are not tied to a particular technology, but to our clients’ needs.
Konplik Health is strong. Our initiative does not respond to a trend, does not seek investors (since we are starting with the personnel, technology, and clients needed to ensure viability and profitability from day one), nor does it seek a quick exit.
Konplik Health is ambitious. Even in this general context of uncertainty, we know that we have enough ingredients to continue innovating and growing in the coming years, and to generate more value for our clients, employees, shareholders, and society as a whole.
Konplik Health is motivated. We are investing the same passion as when we started, with a few more grams of experience.
Thank you for reading such a long post! We are here for you. Please follow us on social media to get to know more about us in the future and do not hesitate to share your thoughts with me at firstname.lastname@example.org.
Thank you so much for your appreciation and support.
Konplik: Transforming Healthcare and Pharma with Artificial Intelligence
Jose C. Gonzalez
CEO, Konplik Health